These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35442407)

  • 21. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT).
    Ramanan AV; Guly CM; Keller SY; Schlichting DE; de Bono S; Liao R; Quartier P
    Trials; 2021 Oct; 22(1):689. PubMed ID: 34627340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
    Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
    Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging drugs for the treatment of noninfectious uveitis.
    Pleyer U; Pohlmann D; Kardeş E; Poddubnyy D; Rademacher J
    Expert Opin Emerg Drugs; 2019 Sep; 24(3):173-190. PubMed ID: 31498689
    [No Abstract]   [Full Text] [Related]  

  • 24. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis.
    Kouwenberg CV; Koopman-Kalinina Ayuso V; de Boer JH
    Acta Ophthalmol; 2022 Jun; 100(4):e994-e1001. PubMed ID: 34532967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Corticosteroid implants for chronic non-infectious uveitis.
    Brady CJ; Villanti AC; Law HA; Rahimy E; Reddy R; Sieving PC; Garg SJ; Tang J
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD010469. PubMed ID: 26866343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis.
    Rathinam SR; Babu M; Thundikandy R; Kanakath A; Nardone N; Esterberg E; Lee SM; Enanoria WT; Porco TC; Browne EN; Weinrib R; Acharya NR
    Ophthalmology; 2014 Oct; 121(10):1863-70. PubMed ID: 24917273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial.
    Rathinam SR; Gonzales JA; Thundikandy R; Kanakath A; Murugan SB; Vedhanayaki R; Lim LL; Suhler EB; Al-Dhibi HA; Doan T; Keenan JD; Rao MM; Ebert CD; Nguyen HH; Kim E; Porco TC; Acharya NR;
    JAMA; 2019 Sep; 322(10):936-945. PubMed ID: 31503307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.
    ; Kempen JH; Altaweel MM; Holbrook JT; Sugar EA; Thorne JE; Jabs DA
    JAMA; 2017 May; 317(19):1993-2005. PubMed ID: 28477440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adalimumab for Treatment of Noninfectious Uveitis: Immunogenicity and Clinical Relevance of Measuring Serum Drug Levels and Antidrug Antibodies.
    Cordero-Coma M; Calleja-Antolín S; Garzo-García I; Nuñez-Garnés AM; Álvarez-Castro C; Franco-Benito M; Ruiz de Morales JG
    Ophthalmology; 2016 Dec; 123(12):2618-2625. PubMed ID: 27692527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
    Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview and recent developments in the medical management of paediatric uveitis.
    Pilly B; Heath G; Tschuor P; Lightman S; Gale RP
    Expert Opin Pharmacother; 2013 Sep; 14(13):1787-95. PubMed ID: 23826652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients.
    Vegas-Revenga N; Calvo-Río V; Mesquida M; Adán A; Hernández MV; Beltrán E; Valls Pascual E; Díaz-Valle D; Díaz-Cordovés G; Hernandez-Garfella M; Martínez-Costa L; Calvo I; Atanes A; Linares LF; Modesto C; González-Vela C; Demetrio-Pablo R; Aurrecoechea E; Cordero M; Domínguez-Casas LC; Atienza-Mateo B; Martín-Varillas JL; Loricera J; Palmou-Fontana N; Hernández JL; González-Gay MA; Blanco R
    Am J Ophthalmol; 2019 Apr; 200():85-94. PubMed ID: 30660771
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized Controlled Study to Evaluate the Efficacy of Adalimumab in Patients with Different Forms of Refractory Uveitis.
    Mackensen F; Heinz C; Jakob E; Grewing V; Lorenz HM; Heiligenhaus A; Max R; Becker MD
    Ocul Immunol Inflamm; 2018; 26(7):1015-1022. PubMed ID: 29286865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New pharmacotherapy options for noninfectious posterior uveitis.
    Pleyer U; Neri P; Deuter C
    Int Ophthalmol; 2021 Jun; 41(6):2265-2281. PubMed ID: 33634341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I.
    Lee K; Bajwa A; Freitas-Neto CA; Metzinger JL; Wentworth BA; Foster CS
    Expert Opin Pharmacother; 2014 Oct; 15(15):2141-54. PubMed ID: 25226529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of biologic agents in the management of uveitis.
    Trivedi A; Katelaris C
    Intern Med J; 2019 Nov; 49(11):1352-1363. PubMed ID: 30582273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterogeneity of primary outcome measures used in clinical trials of treatments for intermediate, posterior, and panuveitis.
    Denniston AK; Holland GN; Kidess A; Nussenblatt RB; Okada AA; Rosenbaum JT; Dick AD
    Orphanet J Rare Dis; 2015 Aug; 10():97. PubMed ID: 26286265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis.
    Park SE; Jun JW; Lee DH; Lee SC; Kim M
    Yonsei Med J; 2021 Feb; 62(2):177-181. PubMed ID: 33527798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis.
    Barry RJ; Tallouzi MO; Bucknall N; Mathers JM; Murray PI; Calvert MJ; Moore DJ; Denniston AK
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012577. PubMed ID: 30562409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.